跳至主導覽 跳至搜尋 跳過主要內容

Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease

  • Shih Chieh Shao
  • , Kai Cheng Chang
  • , Swu Jane Lin
  • , Shang Hung Chang
  • , Ming Jui Hung
  • , Yuk Ying Chan
  • , Edward Chia Cheng Lai*
  • *此作品的通信作者
  • Chang Gung Memorial Hospital
  • National Cheng Kung University
  • University of Illinois at Chicago
  • Chang Gung University
  • Chang Gung Medical Foundation

研究成果: 期刊稿件 › 文章 › 同儕審查

24 引文 斯高帕斯(Scopus)

摘要

Background: The treatment effects on hospitalization for heart failure (hHF) from sodium-glucose cotransporter 2 (SGLT2) inhibitors may vary among type 2 diabetes (T2D) patients depending on whether or not they have established atherosclerotic cardiovascular diseases (ASCVD). We aimed to examine differences in hHF outcomes after dapagliflozin or empagliflozin use between T2D patients with and without a history of established ASCVD. Methods: We conducted a retrospective multi-institutional cohort study in Taiwan. We included T2D patients newly receiving dapagliflozin or empagliflozin during 2016–2019, and followed them up until December 31, 2020. We implemented 1:1 propensity score matching to create homogenous groups for comparisons. We generated Cox proportional hazard models to compare the risk of hHF between dapagliflozin and empagliflozin (reference group). We included interaction terms of SGLT2 inhibitor and ASCVD history in the regression models to examine effect modification by ASCVD. Results: We included a total cohort of 9,586 dapagliflozin new users and 9,586 matched empagliflozin new users. The overall hHF risks were similar for dapagliflozin and empagliflozin (HR: 0.90, 95% CI 0.74–1.09). However, differential hHF risks between dapagliflozin and empagliflozin were observed only in the subgroup without ASCVD (HR: 0.67, 95% CI 0.49–0.90), while not in the subgroup with ASCVD (HR: 1.12, 95% 0.87–1.45), and the p-value for examining interaction was 0.0097. Conclusion: In this study, history of established ASCVD was associated with different hHF risks among SGLT2 inhibitors. For T2D patients without ASCVD, dapagliflozin may offer a more favorable hHF reduction effect, compared to empagliflozin, in clinical practice. Future prospective studies should be conducted to validate our findings.

原文英語
文章編號213
期刊Cardiovascular Diabetology
卷20
發行號1
DOIs
出版品狀態已出版 - 12 2021
對外發佈是

文獻附註

Publisher Copyright:
© 2021, The Author(s).

UN SDG

此研究成果有助於以下永續發展目標

  1. SDG3 健康與福祉
    SDG3 健康與福祉

指紋

深入研究「Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease」主題。共同形成了獨特的指紋。

引用此